News

Key to herbicide resistance
Enlarge image

ResearchUK

Key to herbicide resistance

26.03.2013 - British researchers have found that one single protein seems to control resistance against multiple herbicides of cereal crops weeds.

Multiple-herbicide resistance (MHR) in black-grass and annual rye-grass is a global threat for agriculture, leading to loss of chemical weed control in cereal crops. Until now, it was only poorly understood why MHR is associated with an enhanced ability to detoxify xenobiotics. Assuming an analogy with multiple drug resistance, which occurs in human tumours, researchers from York University and Syngenta now report they have found a possible explanation.

When they searched in black-grass and annual rye-grass for a plant homologue to the MDR causing phi glutathione S transferase (GSTP1) they found an enzyme that also showed both detoxification and signalling. When expressed in Arabidopsis thaliana, the protein termed GSTF1 led to multiple herbicide resistance in the model organism and showed a similar secondary metabolism pattern as the weeds. Those were not associated with a differential gene expression pattern but directly caused by GSTF1.

When they applied the GSTP1 blocker 4-chloro-7-nitro-benzoxadiazole to the weeds, the MHR masterswitch was blocked. They conclude that overexpression of GSTF1 orchestrates multi-herbicide resistance in grass weeds and that targeting the protein is a promising approach to regain weed control in cereal crops.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/masterswitch-for-herbicide-resistance.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products